Third Quarter 2024 Financial Results Cash, cash equivalents, and investments as of September 30, 2024, were approximately $19.7 million. The Company anticipates that its cash, cash equivalents and ...

ALL patients who received Aucatzyl immunotherapy, made from their own T cells, experienced complete remission within three ...

Disclosed on November 13, Neena M Patil, EVP & Chief Legal Officer at Jazz Pharmaceuticals JAZZ -2.13% Get Free Report , ...

Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA ...

SYRS’ Termination of Mid-Stage Leukemia Study in August The latest stock price drop marks the second pipeline setback for Syros in around three months. In August 2024, Syros stock plummeted after it ...

Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 – – Data from the Phase 2a Trial of SLS009 in ...

(Courtesy of Texas Children's Hospital) At Texas Children's Hospital, Fivecoat's daughter Shelly McAfee and her husband Tyler ...

Veteran NBA referee Scott Wall was diagnosed with acute myeloid leukemia earlier this year, the National Basketball Referees ...

NBA referee Scott Wall was diagnosed with acute myeloid leukemia earlier this year and is in treatment, the National ...

In August, Syros discontinued enrollment in the Phase II SELECT-AML-1 trial, in which it was evaluating a triplet regimen of tamibarotene with venetoclax and azacitidine in newly diagnosed, unfit ...

Hematopoietic stem cell transplant (HSCT) after first complete remission appears more effective than non-HSCT consolidation in older patients with AML.